Bioresorbable scaffolds (BRS) provide short-term coronary artery scaffolding and drug delivery. Although prior trials showed a higher rate of device failure compared with conventional drug-eluting stents (DES), only a single trial investigated patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). We aimed to compare outcomes with BRS vs. DES in patients undergoing PCI for MI. 
Introduction
Bioresorbable scaffolds (BRS) represent an innovative stent technology providing short-term coronary artery scaffolding and drug delivery as an alternative to conventional metallic drug-eluting stents (DES). 1 Intuitively, a stent that degrades and is reabsorbed once its scaffolding and drug-releasing function has been served is likely to be preferable to a standard stent. The absence of a long-term stent footprint in the vessel wall removes a potential nidus for late adverse events such as stent thrombosis and restenosis, 2 and permits return of vasomotor function and expansive remodelling in the treated arterial segment. 3, 4 In spite of generally encouraging data from non-clinical investigations and early single-arm clinical studies, 5, 6 prior randomized trials of BRS showed evidence of a higher rate of device failure compared with conventional stents. 7, 8 In particular, the rate of device thrombosis was increased both within the first year 7, 8 and at later time points of follow-up. 9, 10 Subsequently, the manufacturer of the BRS studied in these clinical trials halted production of the device, though a number of similar devices are approved and remain available for use in Europe. 11 In patients undergoing coronary stenting for acute myocardial infarction (MI) a single randomized trial suggested encouraging clinical results with BRS when compared with DES. 12 In fact, patients presenting with MI may be a subgroup of patients who are well suited to treatment with BRS. They are typically younger and more often require treatment of focal, atherothrombotic lesions located in larger vessel segments. 13 Against this background, we did an investigatorinitiated randomized clinical trial, aiming to compare the outcomes of patients treated with BRS vs. conventional stents in patients undergoing stenting for MI.
Methods
The Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) Trial was an investigator-initiated, prospective, randomized, multicentre, noninferiority, clinical trial of everolimus-eluting BRS vs. durable polymer everolimus-eluting stents (EES) in patients undergoing intervention for acute MI. Details of the trial organization and participating sites are provided in the Appendix. The study complied with the Declaration of Helsinki and was approved by the local ethics committee at each participating centre. Written informed consent was obtained from all participants or their legally authorized representatives.
Patient selection and randomization
Patients, 18 years or older, were eligible for enrolment if they presented with ST-elevation MI (STEMI) or in the case of non-ST-elevation MI (NSTEMI) if accompanied by thrombosis visual at angiography, and if stent implantation was planned in de novo lesions in native vessels or coronary bypass grafts with reference vessel diameter > _2.5 mm and < _3.9 mm. The key exclusion criteria were target lesion located in the left main trunk, severely calcified lesions, bifurcation lesions with side branch diameter >2 mm, in-stent restenosis, contraindications to antiplatelet therapy, cobalt chrome, everolimus, polylactic acid, presence of malignancies, or other comorbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance. In each participating centre, allocation to treatment was made by means of sealed, sequentially-numbered, opaque envelopes using a random allocation sequence generated by computer at the trial coordination centre (ISAResearch Center, Munich, Germany). Randomization was done immediately after decision to proceed with intervention and was stratified according to participating centre. Patients who met all of the inclusion criteria and none of the exclusion criteria were randomized in the order that they qualified. Patients were allocated to treatment of the culprit lesion with BRS or EES in a 2:1 proportion. The two treatment groups were studied concurrently. Time zero was defined as the time of randomization. Patients were considered enrolled in the study and eligible for the final intention-to-treat analysis at the time of randomization. Where feasible, the same randomly assigned device was to be implanted in all lesions in those patients requiring non-culprit lesions intervention. Use of more than one device per lesion was permitted.
Study procedures
Patients were treated with intra-arterial or intravenous heparin up to a total amount of 70-100 U/kg body weight or bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure). In patients treated with BRS, implantation technique was at the discretion of the operator. Pre-dilation was strongly encouraged but there was no explicit provision for methods to be used for vessel-and device-sizing nor for post-dilation. After the intervention, all patients received dual antiplatelet therapy according to current guidelines and other cardiac medications at the judgement of the patient's physician (e.g. ß-blockers, ACE-inhibitors, statins etc.). Blood samples were drawn at least once within the first 24 h after randomization and daily afterwards for the determination of cardiac markers (CK, CK-MB, and troponin T) and blood cell counts. Daily recordings of ECG were done until discharge. Clinical follow-up was done at 1 month and 12 months. Repeat coronary angiography was scheduled at 6-8 months. Additional clinical followup will be performed at 2 years. Local research co-ordinators performed primary data collection on source-documented hospital records and entered the relevant data on Case Report Forms. Study monitoring was done on site and remotely by personnel from the ISAResearch Center or delegated organizations in the country of enrolment. The first angiogram (at the time of randomization) and the follow-up angiogram (primary endpoint evaluation) were collected and sent to the Core Laboratory (ISAResearch Center, Munich, Germany) to be evaluated. Angiographic imaging of the target lesion was done in accordance with the Core Laboratory guidelines. Qualitative lesion characteristics were adjudicated based on standard criteria.
14 Quantitative coronary angiographic (QCA) analysis was performed in the 'in-stent' area ('in-stent' analysis) and in the 'in-segment' area including the stented segment as well as both 5 mm areas proximal and distal to the stent margins ('in-segment' analysis) by two-experienced operators using commercially available software (QAngio XA v7.3, Medis, Leiden, Netherlands) according the standard operating procedures of the Core Laboratory.
Study endpoints and organization
The primary endpoint of the study was percentage diameter stenosis insegment at coronary angiography 6-8 months after intervention. The secondary endpoints of the study were the composite of cardiac death/target vessel MI/target lesion revascularization (TLR) (device-oriented composite endpoint), the composite of death/any MI/all revascularization (patient-oriented composite endpoint), the composite of cardiovascular death or MI and the incidence of scaffold or stent thrombosis (definite, probable, and definite/probable). All deaths were assumed cardiovascular in nature unless a noncardiovascular cause could be clearly provided (e.g. malignancy, trauma, and infection). If autopsy was performed autopsy reports were solicited for determination of cause of death. The definition of MI used in this trial was adapted from the Third Universal Definition of Myocardial Infarction. 15 Cardiac troponin was used as the preferred biomarker. CK-MB (and CK) values were assessed concurrently and used in the case that troponin values were not available. Specifically, in the case of NSTEMI with documented stable or falling biomarkers, if the baseline troponin values were elevated and stable or falling, then a rise of >20% was required for the diagnosis of re-infarction, in addition to either symptoms suggestive of myocardial ischaemia or haemodynamic instability, or new ischaemic ECG changes or new left bundle branch block (LBBB), or angiographic loss of patency of a major coronary artery or a side branch, or persistent slow-or no-flow or embolization, or imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality. In the case of NSTEMI with rising biomarkers or STEMI, new symptoms suggestive of myocardial ischaemia or haemodynamic instability were required plus new ischaemic ECG changes or new LBBB plus angiographic loss of patency of a major coronary artery or a side branch or persistent slow-or no-flow or embolization. Device thrombosis/target lesion thrombosis (stent or scaffold) was classified as definite or probable based on Academic Research Consortium criteria. 16 Definite device thrombosis was defined by the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion; probable device thrombosis was defined as unexplained death within 30 days after the procedure or acute MI involving the target-vessel territory without angiographic confirmation. Details of the trial organization are provided in the Appendix. The steering committee was responsible for overseeing the execution and administrative progress of the trial. An independent Event Adjudication Committee was responsible for adjudicating clinical events relevant to the primary and secondary endpoints. Members of the committee were blinded to treatment allocation where feasible.
Statistical analysis
The primary aim of the trial was to test the hypothesis that the Absorb BRS is non-inferior to the durable polymer metallic EES in terms of antirestenotic efficacy as assessed by percentage diameter stenosis insegment at surveillance angiography at 6-8 months. The null hypothesis was that the BRS was inferior to the EES; the alternate hypothesis was that BRS was non-inferior to EES. Analyses were planned to be performed on intention to treat and per protocol datasets. Reported analyses are by intention to treat unless otherwise stated. Subgroup analysis was planned for prespecified subsets of interest according to age, gender, presence of diabetes, type of MI (ST-elevation and non-ST-elevation), and reference vessel size.
For sample size calculation, we assumed a mean percentage diameter stenosis at 6-8 months of 20% in both groups and a common standard deviation (SD) of 12% at angiographic follow-up in patients receiving BRS or EES. 17, 18 The margin of non-inferiority for the primary endpoint was set at 5%. For a power of 80% and a one-sided alpha-level of 0.025 a total number of 206 patients were needed. In order to compensate for possible losses to follow-up, 260 patients were planned to be enrolled. Calculation was done with nQuery Advisor (version 4.0, Statistical Solutions, Cork, Ireland). The data are presented as mean ± SD or median (interquartile range) or counts (%). Categorical variables were compared between treatment groups using the v 2 test with Yates' continuity correction or the Fisher's exact test (where at least one expected cell value <5). Continuous variables were compared using t-test's or Wilcoxon rank sum test as appropriate. Survival analysis was done according to the Kaplan-Meier methods. Hazard ratios (HRs) and P-values for treatment effects were calculated using Cox proportional hazards models. Interaction between treatment effect and subgroup for the primary endpoint was done using multiple linear regression. Sensitivity analysis was done imputing missing data for the primary endpoint using all of the variables listed in Tables 1  and 2 with multiple imputation by chained equations (MICE package, R software). Unless otherwise specified, a two-sided P-value of less than 0.05 was considered to indicate statistical significance. Non-inferiority testing was done with EquivTest (version 1.0, Statistical Solutions, Cork, Ireland) using the methods of Chow and Liu. 19 All other analyses were done with R (version 3.5.0, R Core Team, R Foundation, Vienna, Austria). R.A.B. and A.K. had full access to all the data in the study and take responsibility for its integrity and for the data analysis.
Results
A total of 262 patients were enrolled at five clinical sites in Germany, Spain, Denmark, and Russia between September 2013 and March 2017 (see Supplementary material online, Figure S1 ). Of these, 173 were allocated to BRS and 89 to EES. Baseline patient characteristics were well balanced between the treatment groups ( Table 1) . Overall 203 (77.5%) were male, 197 (75.2%) presented with STEMI, 65 (24.8%) presented with NSTEMI with visible thrombus. Of STEMI patients, 96 (48.7%), 79 (40.1%), and 22 (11.2%) presented with anterior, posterior, and lateral infarction, respectively; 3 (1.5%) patients presented with Killip Class IV.
Baseline lesion and procedural characteristics are shown in Table 2 . Lesion characteristics at presentation were well balanced between the treatment groups. P < 0.001) and post-dilation (56.6% vs. 34.8%, P = 0.001) were more common in patients treated with BRS vs. EES. Post-procedural minimal lumen diameter was lower (2.57 ± 0.43 mm vs. 2.75 ± 0.53 mm, P = 0.003) and percentage diameter stenosis was higher (13.9 ± 9.1% vs. 10.6 ± 5.2%, P < 0.001) with BRS compared with EES. Seven patients did not receive the allocated stent due to either technical reasons or non-compliance with the trial protocol: 5 (2.9%) patients allocated to BRS were treated with EES; of 2 (2.2%) patients allocated to EES, one was treated with BRS and one did not receive a stent.
Two (0.8%) patients died during the index admission. Medications at discharge are shown in Supplementary material online, Table S1 . Two hundred and fifty-five (98.1%) patients received aspirin. All patients received a P2Y12 inhibitor [ticagrelor: 158 (60.8%); prasugrel: 73 (28.1%); clopidogrel: 29 (11.2%)].
Angiographic follow-up was available for 213 (81.3%) patients. Median time to angiographic follow-up was 209 (196-228) days with BRS and 213 (199-234) days with EES (P = 0.61). The results are shown in Table 3 . In terms of the primary endpoint of the trial, mean diameter stenosis in-segment was 24.6 ± 12.2% with BRS vs. 27.3 ± 11.7% with EES, mean difference -2.7%, upper limit of onesided 97.5% confidence limit 0.7%, pre-specified margin of non-inferiority 5%, P non-inferiority < 0.001) (Figure 1 ) in the intention to treat analysis. Findings were consistent in the per protocol analysis (24.4 ± 12.2% with BRS vs. 27.2 ± 11.7% with EES, mean difference -2.8%, upper limit of one-sided 97.5% confidence limit 0.7%, P non-inferiority < 0.001). In a sensitivity analysis with imputed data done to assess bias due to missing follow-up results remained consistent: mean diameter stenosis in-segment was 24.9 ± 12.0% with BRS vs. 26.8 ± 11.4% with EES (mean difference -1.9%, upper limit of one-sided 97.5% confidence limit 1.2%, P non-inferiority < 0.001). There were no cases of complete vessel occlusion at planned follow-up angiography.
Clinical follow-up to 12 months was complete in all but one patient; this patient had follow-up to 30 days. The results are shown in Table 4 . The composite of cardiac death/target vessel MI/TLR (device-oriented composite endpoint) occurred in 12 (7.0%) patients treated with BRS vs. 6 (6.7%) with EES [HR 1.04, 95% confidence interval (CI) 0.39-2.78] (Figure 2A) All four cases of definite device thrombosis occurred during the index hospital stay, three of them within 2 h of the procedure, and one on Day 3 (which was noted incidentally at angiography planned to evaluate an additional lesion). Of the three cases occurring within 2 h, two were adjudicated to have fulfilled the additional criteria for re-infarction, and one was not.
In the terms of the primary endpoint, results were consistent across pre-specified subgroups of interest according to age, gender, vessel size, and presence or absence of diabetes ( Figure 3) . There was evidence of interaction in relation to type of MI at presentation (for STEMI: BRS 23.7 ± 11.4 vs. EES 29.3 ± 12.1, P = 0.002; for NSTEMI: BRS 27.8 ± 14.5 vs. EES 22.2 ± 8.8, P = 0.35; P interaction = 0.004). In relation to the device-oriented composite results were consistent Table S2 ).
Discussion
The main finding of this randomized trial was that in patients presenting with acute MI undergoing coronary stenting, treatment with BRS was not inferior to EES in terms of the primary endpoint of percentage diameter stenosis at follow-up angiography. Moreover, in subgroup analysis there was evidence of interaction between type of acute MI and treatment effect, such that in patients presenting with STEMI percentage diameter stenosis was lower with BRS, whereas in patients presenting with NSTEMI no difference was observed. The rates of the main secondary outcomes including a device-oriented composite endpoint and stent thrombosis were comparable in both groups.
Limitations
The finding of non-inferiority of BRS in comparison with conventional stents is potentially important but requires cautious interpretation for a number of reasons. First, we used a surrogate endpoint of device efficacy as primary endpoint of our trial. However, prior investigations have shown that percentage diameter stenosis is a robust parameter of device efficacy. 20, 21 Second, although clinical outcomes were also broadly comparable between the groups, the trial was not powered to detect differences between the treatment groups and the risk of Type II error is high. Third, the duration of follow-up was limited to 12 months. However, the absence of difference between the two devices at this time in our trial might be interpreted against the background of earlier trials, 7, 8, 22 which showed a clear of excess of adverse events with BRS in the first 12 months. Nevertheless, prior studies subsequently showed evidence of late adverse events related to scaffold discontinuity 23, 24 and longer-term follow-up of this trial is warranted to inform whether late performance differences will emerge between devices. In addition, details of cardiovascular medications at 1 year were not captured in our study.
Prior clinical trials
Our findings are broadly consistent with those of an earlier randomized trial comparing clinical results with BRS vs. convention DES in patients with acute MI. 12 In that trial-TROFI-II 191 patients with STEMI were randomly allocated to treatment with BRS or EES. The primary endpoint was an intravascular imaging surrogate parameter of vessel healing, which was lower-indicating more favourable healing-with BRS when compared with EES [ Months after randomization Target-lesion revascularization (%) 
Patient selection and procedural considerations
Indeed, it is generally accepted that appropriate lesion selection plays a critical role for the clinical performance of BRS. It is plausible that patients with acute MI may represent a niche group that may derive greater benefit from treatment with BRS. A number of factors could explain this observation. First, patients presenting with STEMI or non-STEMI with visible thrombus more often present with proximal lesions in larger vessels. Moreover, lesion morphology is less complex and less often heavily calcified with a high proportion of thin cap, necrotic core fibroatheromatous plaques. This substrate may be inherently well-suited to treatment with BRS by offering less mechanical resistance to stent deployment and facilitating better implantation of the relatively thick struts of BRS. Second, patients with acute MI are usually more aggressively treated with antithrombotic therapy both in the acute phase (higher cumulative doses of heparin, more frequent glycoprotein receptor antagonist therapy) and over the course of the initial 12 months (more potent P2Y12 inhibitors typically used). 26 This may mitigate the increased risk of stent thrombosis observed in earlier trials in the first year after implantation, 7, 8 which is possibly related to the suboptimal deployment of BRS in comparison with conventional stents. In addition to patients with STEMI, we also included patients with NSTEMI and angiographic evidence of thrombosis, as we hypothesized that the pathophysiology of these two types of presentation may have a number of similarities. Interestingly, we saw an interaction between treatment effect and type of MI. More favourable results were seen for BRS in terms of the primary endpoint in patients with STEMI, with less favourable results in patients with NSTEMI. Although the reasons for this difference are not clear and could be due to chance, it may well be that thin cap, necrotic core plaques more commonly seen in STEMI are better substrates for BRS treatment. While no evidence of interaction between treatment arm and the other pre-specified subgroups of interest was seen, the results of Figure 3 Primary endpoint analysis for prespecified subgroups. Mean percentage diameter stenosis at follow-up angiography for prespecified subgroups according to age (>median and < _median), gender, presence or absence of diabetes, presentation with ST-elevation myocardial infarction or non-ST-elevation myocardial infarction, and reference vessel diameter (<median and > _median); difference in mean for each subgroup with 95% confidence intervals is shown graphically. BRS, bioresorbable scaffold; CI, confidence interval; EES, everolimus-eluting stent.
interaction testing must be considered with caution due to the modest sample size.
In terms of implantation technique for BRS, in our trial, we did not make specific recommendations for operators regarding vessel sizing or post-dilation in particular. Accordingly, pre-dilation was frequently done in patients with BRS (>95%), which is in keeping with consensus about the implantation of these devices since their approval for clinical use in Europe. Vessel sizing can be challenging in the setting of acute MI, and both intravascular imaging and online quantitative analysis are likely to be less reliable than in stable patients. Using standard visual assessment and operator judgement mean scaffold diameter was approximately 10% larger than mean QCA-measured reference vessel diameter pre-implantation. Post-dilation was done in just over 50% of cases. Accordingly, we feel that the implantation technique is likely to have high-external validity and be generalizable for routine practice.
Although the BRS investigated in our trial is no longer commercially available, a number of other devices are in various stages of development and testing. 11 In our opinion, the results observed in our trial provide a rationale for testing existing BRS and new devices or iterations of existing devices in patients with acute MI. In addition to the encouraging results observed, the potential benefit is also greater as these patients are usually younger and have less extensive disease patterns.
Conclusion
In conclusion, in patients undergoing intervention for acute MI, BRS were non-inferior to EES for percentage diameter stenosis at angiographic follow-up. In addition, rates of secondary clinical endpoints including a device-oriented composite endpoint and device thrombosis were comparable between the treatment groups, although the study was not powered to detect differences in clinical outcomes. Acute MI, with STEMI in particular, may represent a clinical setting in which further assessment of BRS is warranted.
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